Literature DB >> 10426202

Oral manifestations as a hallmark of malignant acanthosis nigricans.

V Ramirez-Amador1, L Esquivel-Pedraza, E Caballero-Mendoza, J Berumen-Campos, R Orozco-Topete, A Angeles-Angeles.   

Abstract

We present a case of malignant acanthosis nigricans (AN) that initially manifested in the oral cavity. In the present report, the patient had typical clinical and histological findings of oral and esophageal AN, with subtle skin changes, associated with a gallbladder adenocarcinoma. The importance of the clinical oral examination is emphasized because the recognition of oral lesions led to the diagnosis of AN and to the following detection of the internal malignancy. Since the tumours associated with AN are highly malignant, it is of the utmost importance to recognize the skin and mucous membrane changes in adults.

Entities:  

Mesh:

Year:  1999        PMID: 10426202     DOI: 10.1111/j.1600-0714.1999.tb02039.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  4 in total

1.  Occult cause of paraneoplastic acanthosis nigricans in a patient with known breast dcis: case and review.

Authors:  B D Jakubovic; H F Sawires; D N Adam
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

Review 2.  Rabson-Mendenhall syndrome: two case reports and a brief review of the literature.

Authors:  Renuka J Bathi; Sameena Parveen; Sunil Mutalik; Reema Rao
Journal:  Odontology       Date:  2010-02-16       Impact factor: 2.634

Review 3.  Small cell gallbladder carcinoma complicated by paraneoplastic hyponatremia: a case report and literature review.

Authors:  Esther S Ng; Kotamma Venkateswaran; Shridhar I Ganpathi; Benjamin Y Chuah
Journal:  J Gastrointest Cancer       Date:  2010-12

4.  Malignant Acanthosis Nigricans with Recurrent Bladder Cancer: A Case Report and Review of Literature.

Authors:  Rongxin Zhang; Meiya Jiang; Wenyi Lei; Aoxue Wang
Journal:  Onco Targets Ther       Date:  2021-02-10       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.